Iniciar sesión Regístrese gratis

Last updated: 11 June 2024 at 7:19pm EST

Sandeep Laumas Net Worth



Sandeep Laumas BTAI stock SEC Form 4 insiders trading

Sandeep has made over 16 trades of the BioXcel Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of BTAI stock worth $4,600 on 28 June 2019.

The largest trade he's ever made was buying 5,000 units of BioXcel Therapeutics Inc stock on 22 May 2019 worth over $6,900. On average, Sandeep trades about 1,268 units every 11 days since 2018. As of 28 June 2019 he still owns at least 18,000 units of BioXcel Therapeutics Inc stock.

You can see the complete history of Sandeep Laumas stock trades at the bottom of the page.





Sandeep Laumas biography

Dr. Sandeep Laumas M.D. serves as Independent Director of the Company. He has served as a Director of BioXcel Corporation since May 2013. On February 18, 2019, Dr. Laumas was appointed chief executive officer of Innovate Biopharmaceuticals, Inc., a biopharma company and has served as its Executive Chairman since 2018. In August 2007, Dr. Laumas founded Bearing Circle Capital, LP, an investment partnership, and has served as its Managing Director since such time. Dr. Laumas began his career at Goldman Sachs & Co. in 1996 as an equity analyst in the healthcare investment banking division working on mergers, acquisitions and corporate finance transactions before transitioning to the healthcare equity research division. After leaving Goldman Sachs in 2000, Dr. Laumas moved to the buy side as an analyst at Balyasny Asset Management from 2001 to 2003. Dr. Laumas was a Managing Director of North Sound Capital from 2003 to 2007, where he was responsible for the global healthcare investment portfolio. From February 2011 to 2012 he was a member of the board of directors of Super Religare Laboratories Limited, Southeast Asia's largest clinical laboratory service company. Dr. Laumas also served as a Director of Parkway Holdings Ltd. from May to August 2010 Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research gap year at the Dana-Farber Cancer Institute and completed his medical internship in 1996 from the Yale University School of Medicine. Dr. Laumas has a novel industry perspective, particularly in both public and private investments and financial transactions in the healthcare arena, which we believe qualifies him to serve as a director of our company.

What is the salary of Sandeep Laumas?

As the Independent Director of BioXcel Therapeutics Inc, the total compensation of Sandeep Laumas at BioXcel Therapeutics Inc is $174,603. There are 6 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of $1,968,930.



How old is Sandeep Laumas?

Sandeep Laumas is 51, he's been the Independent Director of BioXcel Therapeutics Inc since 2017. There are 11 older and 3 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.

What's Sandeep Laumas's mailing address?

Sandeep's mailing address filed with the SEC is 8480 Honeycutt Rd #120, Raleigh, NC 27615, USA.

Insiders trading at BioXcel Therapeutics Inc

Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta y Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.



What does BioXcel Therapeutics Inc do?

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.



What does BioXcel Therapeutics Inc's logo look like?

BioXcel Therapeutics Inc logo

BioXcel Therapeutics Inc executives and stock owners

BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: